Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMM47 in advanced solid tumors
NCT05985083Phase 1Unknown
- Sponsor
- ImmuneOnco
- Start
- Aug 2023
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of IMM47 in solid tumor (advanced stage), sponsored by ImmuneOnco. Primary endpoints: Dose-Limiting Toxicities at 28 days, Maximum Tolerated Dose at 48 weeks and 3 more. Status: unknown.
02
Drugs
IMM47
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT05985083.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05985083.